Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma.
about
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.Spotlight on vismodegib in the treatment of basal cell carcinoma: an evidence-based review of its place in therapy.Sonidegib: mechanism of action, pharmacology, and clinical utility for advanced basal cell carcinomas.From basal cell morphogenesis to the alopecia induced by hedgehog inhibitors: connecting the dots.Vismodegib for Locally Advanced Periocular and Orbital Basal Cell Carcinoma: A Review of 15 Consecutive Cases.Skin Cancer Epidemics in the Elderly as An Emerging Issue in Geriatric OncologyVismodegib for recurrent locally destructive basal cell carcinoma in a renal transplant patient.Vismodegib persistence and discontinuation patterns in Greek patients from a real world setting.Treatment of advanced basal cell carcinoma with sonidegib: perspective from the 30-month update of the BOLT trial.Acute generalized exanthematous pustulosis simulating Stevens-Johnson syndrome/toxic epidermal necrolysis associated with the use of vismodegib.Recovery of taste organs and sensory function after severe loss from Hedgehog/Smoothened inhibition with cancer drug sonidegib.[The aged scalp : A dermato-oncological focus point].Management of the cutaneous adverse effects of antimelanoma therapySpecies generalization and differences in Hedgehog pathway regulation of fungiform and circumvallate papilla taste function and somatosensation demonstrated with sonidegib
P2860
Q33691572-9BFB5FC9-318E-441A-A61F-EFD039DCA457Q33703696-D541D49E-7394-4359-8B6B-FE6F23ECF975Q37714065-372D96DC-41E8-475A-BA5C-E36168C55DB0Q39381932-915DCF6E-BCCC-44E9-812C-9B38EFD244B4Q41306560-23C6BC49-2F7D-48E9-8F80-5F9C19E79BEBQ41952060-4BE5087F-00BD-4262-B05C-BA88AD7175CCQ42511464-456878CA-AB72-43BD-95CF-7C0D05D1464EQ42516264-E90F9AAF-7696-430C-B549-E1C1005AE3AFQ47627322-4D3CFC0B-CAE3-4FB4-B449-9B8F8094F221Q49507301-F9B8BC87-7C76-49E7-AB4D-3744B9A63224Q50043217-7B62FB87-5954-41B3-BD42-ED457EBC9032Q51821884-8DD683A0-961A-4579-9FDB-D461E359DFAEQ56893430-E943AE3D-80EE-4916-B1D5-79CEA2D1485BQ58577830-DFFBB5B8-5894-4FFE-9D3B-2615BA945B64
P2860
Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 August 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Characterization and Managemen ...... Advanced Basal Cell Carcinoma.
@en
Characterization and Managemen ...... Advanced Basal Cell Carcinoma.
@nl
type
label
Characterization and Managemen ...... Advanced Basal Cell Carcinoma.
@en
Characterization and Managemen ...... Advanced Basal Cell Carcinoma.
@nl
prefLabel
Characterization and Managemen ...... Advanced Basal Cell Carcinoma.
@en
Characterization and Managemen ...... Advanced Basal Cell Carcinoma.
@nl
P2093
P2860
P50
P921
P1433
P1476
Characterization and Managemen ...... Advanced Basal Cell Carcinoma
@en
P2093
Aleksandar Sekulic
Axel Hauschild
Brigitte Dréno
Jonas Sokolof
Ketty Peris
Nicole Basset-Seguin
Paolo Antonio Ascierto
Rainer Kunstfeld
Reinhard Dummer
P2860
P304
P356
10.1634/THEONCOLOGIST.2016-0186
P577
2016-08-10T00:00:00Z